Endocrine and bone diseases

15 public biotech companies we cover are developing treatments for thyroid, parathyroid, growth and pituitary disorders, menopause and bone diseases. 10 upcoming catalysts are listed below, with dates as the companies gave them.

Companies

AbCellera Biologics (ABCL)Thesis Intact
Vasomotor symptoms due to menopause
Ascendis Pharma (ASND)Thesis Challenged
Osteoporosis, Achondroplasia, Shox deficiency, Hypochondroplasia, and 4 more
Biohaven (BHVN)Thesis Challenged
Graves' disease
BridgeBio Pharma (BBIO)Thesis Intact
ADH1, Achondroplasia, Hypochondroplasia, Chronic hypoparathyroidism, and 1 more
Immunovant (IMVT)Thesis Challenged
Graves Disease
Lipocine (LPCN)Thesis Broken
Male hypogonadism
NextCure (NXTC)Thesis Broken
Osteogenesis imperfecta
Profound Medical (PROF)Thesis Intact
Adenomyosis, Osteoid osteoma, Uterine fibroids
Recursion Pharmaceuticals (RXRX)Thesis Intact
Hypophosphatasia
Rezolute (RZLT)Thesis Challenged
Tumor hyperinsulinism
Roivant Sciences (ROIV)Thesis Intact
Graves disease
Tonix Pharmaceuticals (TNXP)Thesis Challenged
Arginine-vasopressin deficiency
Ultragenyx Pharmaceutical (RARE)Thesis Challenged
Osteogenesis imperfecta, X-linked hypophosphatemia, Tumor-induced osteomalacia
Viridian Therapeutics (VRDN)Thesis Intact
Graves disease
Xeris Biopharma (XERS)Thesis Intact
Hypothyroidism, Cushing's syndrome

Drug pages

Encaleret

Upcoming catalysts

Firm dates · a specific day set by the company or regulator

Later

Feb 4
in 102 days
Infigratinib · FDA decision · Achondroplasia
BridgeBio Pharma (BBIO)·Source
May 8
in 195 days
Encaleret · FDA decision · Autosomal dominant hypocalcemia type 1
BridgeBio Pharma (BBIO)·Source
May 8
in 195 days
Encaleret · FDA decision · ADH1
BridgeBio Pharma (BBIO)·Source

Estimated timing · a month, quarter, half-year or year-end the company gave

Expected in December 2026

December 2026
Ersodetug · Phase 3 topline results (upLIFT) · Tumor hyperinsulinism
Rezolute (RZLT)·Source

Expected in Q4 2026

Q4 2026
TransCon CNP · EU regulatory decision · Achondroplasia · pediatric 2+ years
Ascendis Pharma (ASND)·Source
Q4 2026
Infigratinib · MAA submission · Achondroplasia
BridgeBio Pharma (BBIO)·Source
Q4 2026
XP-8121 · Phase 3 start (Cornerstone) · Hypothyroidism
Xeris Biopharma (XERS)·Source

Expected in H2 2026

H2 2026
TransCon CNP · Phase 3 start · Hypochondroplasia
Ascendis Pharma (ASND)·Source
H2 2026
Infigratinib · Phase 2 results · Hypochondroplasia
BridgeBio Pharma (BBIO)·Source
H2 2026
REV102 · Phase 1 start · Hypophosphatasia
Recursion Pharmaceuticals (RXRX)·Source